Merck gets nod from FDA for Dulera

WHITEHOUSE STATION, N.J. The Food and Drug Administration has approved a new drug by Merck for treating asthma in patients ages 12 years and older, Merck said Thursday.

The FDA approved Dulera (mometasone furoate and formoterol fumarate dihydrate), an inhaled, fixed-dose combination asthma treatment.

“Despite the advances made in the treatment of asthma in recent years, many patients may still not be well-controlled on their current therapies,” University of Tennessee Health Science Center medical professor Michael Blaiss said in a statement on behalf of Merck. “Asthma control is an important treatment goal, and Dulera provides a new option for physicians to help manage this chronic condition in appropriate patients.”

Login or Register to post a comment.